Abstracts tagged "spondyloarthritis"

Abstract Number: 2310 • ACR Convergence 2025
Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
ELENA GRAU GARCIA¹, SAMUEL LEAL², Jose Ivorra Cortes³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Daniel Ramos Castro⁶, Alba Maria Torrat Noves⁷, Iago Alcantara Alvarez⁸, Belen Villanueva Manes⁹, Miguel Simeo Vinaixa⁸, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Spain, ⁹Hospital La Fe, València, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: NGFβ and CGRP are neuropeptides with a significant role in peripheral inflammation, pain modulation and immune responses. Neuropeptides regulatory mechanisms in spondyloarthritis (SpA) remain…
Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Christopher Ritchlin¹, Javier Rangel-Moreno², Angel Rangel-Garcia³, Marissa Krantz⁴, Madison Brien², Thiloginy Sathilaseenlan², Jeffrey Fox⁵, Ronald Wood² and Maria de la Luz Garcia-Hernandez³, ¹University of Rochester Medical Center, Canandaigua, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, West Henrietta, NY, ⁴University of Rochester, Bethesda, MD, ⁵University od Rochester, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…
Abstract Number: 1423 • ACR Convergence 2025
Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
Meghna Gavali¹, Husna Fatima², Bhavya Sirivelu³, Nishanth S³ and Noorjahan M³, ¹nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ²Nizami Institute of Medical Sciences, Hyderabad, Telangana, India, ³Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder primarily affecting the axial skeleton and associated with HLA-B27. Non-HLA genes, including ERAP1 (Endoplasmic Reticulum Aminopeptidase…
Abstract Number: 0578 • ACR Convergence 2025
Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease¹, Xiaolan Ye², Christopher Saffore³, Thomas Iyile⁴, Nicole Middaugh⁵, Taylor Blachley⁵, Melissa Eliot⁵ and Alexis Ogdie⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease that can cause substantial impairment in quality of life in affected patients. The Group for Research…
Abstract Number: 0540 • ACR Convergence 2025
Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Manouk de Hooge¹, Mary Lucy Marques², Gizem Ayan³, Miranda van Lunteren⁴, Liese de Bruin⁴, Monique Reijnierse⁵, Désirée Van Der Heijde⁴, Sofia Ramiro⁶ and Floris A. van Gaalen⁴, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, ³Ankara Research and Training Hospital, Ankara, Turkey, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Low-dose computed tomography (ldCT) has not previously been used to assess pt with axial spondyloarthritis (axSpA) early in their disease course, especially those with…
Abstract Number: 0386 • ACR Convergence 2025
Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: The West Haven-Yale Multidimensional Pain Inventory (MPI) is a validated tool designed to assess the multidimensional aspects of chronic pain, including the 5 dimensions…
Abstract Number: 2349 • ACR Convergence 2025
Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
Gözde Sevgi Kart bayram¹, Muhammed Çağrı Akdemir², Mustafa Ekici³, Gizem Ayan⁴, Büşra Fırlatan Yazgan¹, Erdinç Ünaldı³, Buğu Bulat¹, Ali Aytuğ Kuştaş³, Ali Akdoğan⁵, Omer Karadağ⁵, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Sedat Kiraz³, Umut Kalyoncu¹ and Levent Kılıç¹, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Ankara, Turkey, ⁴Ankara Research and Training Hospital, Ankara, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara
Background/Purpose: The concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA)[1], may vary over time. Transitions between D2M and non-D2M classifications throughout the disease course remain unclear. This…
Abstract Number: 2308 • ACR Convergence 2025
Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
AUGUSTA ORTOLAN¹, Désirée Van Der Heijde², Laure Gossec³ and Sofia Ramiro⁴, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Health-related quality of life (HRQoL) is an overarching outcome in axial spondyloarthritis (axSpA), and is considered influenced by disease activity and physical function. However,…
Abstract Number: 1466 • ACR Convergence 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Walter P. Maksymowych¹, Robert G. W. Lambert², Victoria Navarro-Compan³, Xenofon Baraliakos⁴, Jason Coarse⁵, Natasha de Peyrecave⁶ and Mikkel Ostergaard⁷, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB, Morrisville, NC, ⁶UCB, Brussels, Belgium, ⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Spinal inflammation and structural progression are key features of radiographic axial spondyloarthritis (r-axSpA).1 Canada-Denmark (CANDEN) scoring enables anatomical-based assessments of MRI inflammatory and structural…
Abstract Number: 1420 • ACR Convergence 2025
A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Isadora Small¹, Anuya Natu² and Augustine Manadan³, ¹The Latin School of Chicago, Chicago, IL, ²John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with systemic complications that may contribute to increased mortality risk. This study examines the characteristics and…
Abstract Number: 0575 • ACR Convergence 2025
Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
Laia De Daniel Bisbe¹, Jesús Rodriguez², Laura Berbel³, Joan Miquel Nolla¹, Aina Fabregat², Monica Cubells² and Diego Benavent Nuñez², ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital Universitari de Bellvitge, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease combining psoriasis (Pso) and arthritis. Despite the availability of multiple therapeutic options, many patients experience residual…
Abstract Number: 0539 • ACR Convergence 2025
Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
Liese de Bruin¹, Floris A. van Gaalen¹, Manouk de Hooge², Miranda van Lunteren¹, Mary Lucy Marques³, Monique Reijnierse⁴, Roberta Ramonda⁵, Inger Jorid Berg⁶, Sofia Exarchou⁷, Robert Landewé⁸, Désirée Van Der Heijde¹ and Sofia Ramiro⁹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, ⁴Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy, ⁶⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Nepal, ⁷Lund University, Åkarp, Skane Lan, Sweden, ⁸Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The assessment of structural damage progression is an important part of outcome assessment in axial SpA (axSpA). In order to test whether interventions can…
Abstract Number: 0275 • ACR Convergence 2025
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Stefano Gentileschi¹, Carla Gaggiano¹, Francesco Placido¹, Riccardo Terribili¹, Laura Cometi², Giuseppe Lopalco³, Greta Dipetrangelo³, Giacomo Cozzi⁴, Roberto Padoan⁵, Riccardo Bixio⁶, Simone Parisi⁷, Maria Chiara Ditto⁸, Gemma Lepri⁹, Caludia Fabiani¹⁰, Luca Cantarini¹, Florenzo Iannone¹¹, Roberta Ramonda¹², Bruno Frediani¹ and Serena Guiducci², ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy, ²Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ³Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University o f Bari, Bari, Italy, Bari, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, Padua, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ⁶Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, Verona, Italy, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸SC Reumatologia, AOU Città della Salute e della Scienza, Torino, Italy, Turin, Italy, ⁹Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹⁰Ophthalmology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena University Hospital [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, Siena, Italy, ¹¹Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹²Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: A new subcutaneous formulation of infliximab (CT-P13) has recently become available for the treatment of inflammatory rheumatic diseases (IRDs), psoriasis and inflammatory bowel diseases.…
Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Francesco Fulvio Bizzarri¹, Luis Alberto Menchén Viso², Esther Chamorro De Vega³, Ofelia Baniandrés Rodríguez⁴ and Juan Carlos Nieto², ¹Hospital Universitario Clinico San Cecilio, Granada, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…
Abstract Number: 2307 • ACR Convergence 2025
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
AUGUSTA ORTOLAN¹, Casper Webers², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Maastricht University Medical Centre, Maastricht, Netherlands, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral manifestations (peripheral arthritis, enthesitis, dactylitis) of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) represent a significant burden for patients, but are understudied. Our…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].